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Abstract: The number of patients with type 2 diabetes continues to rise; an anticipated 300 
million people will be affected by 2025. The immense social and economic burden of the con-
dition is exacerbated by the initial asymptomatic nature of type 2 diabetes, resulting in a high 
prevalence of micro- and macrovascular complications at presentation. Diabetic retinopathy, 
one of the potential microvascular complications associated with diabetes, and neovascular 
age-related macular degeneration (AMD) are the two most frequent retinal degenerative dis-
eases, and are responsible for the majority of blindness due to retinal disease. Both conditions 
predominantly affect the central macula, and are associated with the presence of retinal edema 
and an aggressive inﬂ  ammatory repair process that accelerates disease progression. The associ-
ated retinal edema and the inﬂ  ammatory repair process are directly involved in the breakdown 
of the blood-retinal barrier (BRB). Yet, the underlying alterations to the BRB caused by the 
diseases are very different. The coexistence of the two conditions appears to be relatively 
uncommon, suggesting that diabetes may even protect patients from developing neovascular 
AMD. However, it is thought that the inﬂ  ammatory repair responses associated with diabetic 
retinopathy and neovascular AMD may be cumulative and, in patients affected by both, could 
result in chronic diffuse cystoid edema. Treatment considerations in such patients should, 
therefore, include the role of retinal edema and the increased susceptibility of patients with 
diabetes to potential systemic side effects associated with agents administered repeatedly for 
neovascular AMD treatment.
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Introduction
In 1999, the World Health Organization (WHO) reclassiﬁ  ed the biochemical and 
etiological deﬁ  nitions of diabetes mellitus (see Table 1) (WHO 1999). These changes 
were helpful in better identifying individuals associated with progressively greater 
risk of developing the pathognomonic microvascular and macrovascular complica-
tions associated with diabetes.
Diabetes prevalence
Type 2 diabetes represents more than 85% of all cases of diabetes. The WHO esti-
mated that worldwide, 150 million people over the age of 20 years had the condition 
in 2000, a number set to rise to 300 million people by 2025 (King et al 1998). The 
prevalence varies enormously between countries, depending upon numerous genetic 
and environmental factors. However, the greatest burden appears to be in India, China, 
the US, Pakistan, Indonesia, the Russian Federation, Mexico, and Brazil, which col-
lectively account for more than half of all cases globally (King et al 1998). Expressed 
as age-speciﬁ  c prevalence, less than 10% of the European population under 60 years 
old have type 2 diabetes, yet this increases to 10%–20% in those aged 60–79 years 
(DECODE 2003).Clinical Ophthalmology 2008:2(2) 370
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Worryingly, the incidence of pediatric type 2 diabetes is 
rising and, exceeds 4% in American Indians aged between 
15–19 years (Dabelea et al 1998). The asymptomatic nature 
of this condition, common until complications emerge, 
increases the burden of diabetes as, for example, up to one 
third of patients may have retinopathy at diagnosis. There is 
a resultant need for more widespread, efﬁ  cient screening to 
enable earlier capture of new cases, but there is no universal 
agreement as to how this can be best achieved.
In contrast to type 2 diabetes, the relatively abrupt onset 
of type 1 diabetes usually negates the likelihood of diabetic 
complications at diagnosis (less than 2% of patients have 
retinopathy at presentation). It is estimated that 10–20 million 
individuals suffer from this condition globally (Rewers et al 
1988). Type 1 diabetes peaks in patients under the age of 
15 years (with prevalence of up to 0.3%) and has dramatic 
geographic variability. A child in Finland, for example, is 
400 times more likely to develop type 1 diabetes than a child 
in China (Steck et al 2004).
The burden of diabetes
The implications of diabetes are immense at an individual, 
caregiver and societal level. When considering some of the 
potential burdens faced by individuals with diabetes, as sum-
marized in Table 2, it is not surprising that these patients are 
prone to states of depression and anxiety (Gavard et al 1993).
The Costs of Diabetes in Europe-2 (CODE-2) Study 
(Baxter et al 2000) and T2ARDIS Study (GSK 2000) 
perhaps provide the most robust data on the economic burden 
associated with diabetes across Europe. These studies have 
identiﬁ  ed that the healthcare costs associated with patients 
with diabetes are more than twice those of age-matched 
individuals without diabetes. Using a UK-based model, this 
lifetime cost equates to £33,000 for male patients and £43,000 
for female patients, compared with £15,000 for men and 
£22,000 for women without diabetes (Bagust et al 2001).
CODE-2 also demonstrated that the costs of those patients 
with microvascular complications, such as retinopathy, are 
nearly twice those associated with patients without complica-
tions. These calculations underestimate the true cost burden 
associated with diabetes as they fail to take into account 
absence from work, early retirement or premature death 
due to the condition. Evidence from studies in both type 1 
(DCCT 1996) and type 2 (UKPDS 2000) diabetes suggest 
that better glycemic control is cost-effective in reducing 
diabetes-associated morbidity and mortality. Systematic 
screening for diabetic complications such as retinopathy has 
also been shown to be a cost-effective intervention (James 
et al 2000).
The pathogenesis of diabetes
Type 1 process
Type 1 diabetes indicates the presence of underlying pancre-
atic beta-cell destruction with a progressive decline in insulin 
production and secretion. Exogenous insulin administra-
tion is required for survival to prevent the development of 
Table 1 WHO classiﬁ  cation of diabetes mellitus (WHO 1999)
*Fasting venous plasma  7.0 mmol/L
*Random venous plasma  11.1 mmol/L
Type 1 (beta-cell destruction, usually absolute insulin 
deﬁ  ciency)
1A Autoimmune
1B Idiopathic
Type 2 (range from predominant insulin resistance to 
predominantly secretory defect ± insulin resistance)
Other speciﬁ  c types
Genetic defects of beta cell function or insulin action
Diseases of the exocrine pancreas
Endocrinopathies
Drug/chemical induced
Infections
Rare immune-mediated forms
Other genetic disorders associated with diabetes
Gestational diabetes
*One abnormal blood glucose measurement is sufﬁ  cient in the presence of symptoms, 
but for the asymptomatic person at least one additional plasma/blood glucose test 
result with a value in the diabetic range is essential.
Table 2 Examples of the individual burden of diabetes
Lifestyle Dietary, exercise, and changes to other factors associated 
with diabetes
Monitoring and management of diabetes
Restrictions for sports and other leisure activities
Vehicle driving limitations
Work Restrictions on occupations
Implications at work for monitoring/managing diabetes
Clinical Need for regular health checks/blood tests
The development (or fear of development) of diabetic 
complications and their implications
Greater likelihood of hospital admission
Often the need for regular medication with risks of side 
effects
Increased risk of other conditions associated with 
diabetes
Financial Costs of treatment (in non-state health subsidized 
societies)
Loading of health-related insurances
Loss of income through diabetes-related illnessClinical Ophthalmology 2008:2(2) 371
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ketoacidosis, coma and death. Type 1A diabetes is thought to 
arise from a chronic autoimmune destruction of the pancreatic 
beta cells, usually initiated by exposure of genetically suscep-
tible individuals to environmental agents. This event is usually 
a cell-mediated immune process and is characterized by the 
presence of islet cell, insulin or glutamic acid decarboxylase 
(GAD) autoantibodies. Genetic inﬂ  uences include the pres-
ence of susceptibility genes, such as in the human leukocyte 
antigen (HLA) region on chromosome 6p21, which accounts 
for nearly half of familial clustering. Potential environmental 
factors have implicated viruses (eg, herpes virus, mumps, 
rubella, and retroviruses), perinatal factors, dietary factors, 
and exposure to toxins (Steck and Rewers 2004).
Type 1B diabetes refers to a heterogeneous group of 
individuals who show no evidence of autoimmune destruc-
tion of pancreatic beta cells; they account for up to 40% of 
patients with type 1 diabetes (Urakami et al 2002).
Type 2 process
The process underling type 2 diabetes is insulin resistance 
and defective insulin secretion, either of which predominates. 
Type 2 diabetes is heterogeneous and has many distinct 
causes. However, most patients are obese with concomitant 
insulin resistance and fulﬁ  ll the classiﬁ  cation of the metabolic 
syndrome (see Table 3) (Alberti et al 1998).
Diabetic complications
Macrovascular
The major abnormality present in diabetes is atherosclerosis 
(Kannel et al 1979), usually preceded by endothelial 
dysfunction. Much debate surrounds whether this is an 
exaggeration of the process seen in non-diabetic subjects, 
or whether there are specific features pathognomonic 
of diabetes. Overall, diabetes seems to be associated 
with an increase in amount, extent, and distribution of 
atherosclerosis leading to susceptibility to ischemic heart 
disease, cerebrovascular and peripheral vascular disease 
and erectile dysfunction. The association between glycemic 
control and macrovascular disease is less pronounced 
compared with other vascular risk markers such as smoking, 
hypertension and dyslipidemia.
Microvascular
Microvascular complications consist of pathological changes 
that mainly affect the function of the retina, kidney and 
neurological system, and a much more established link to 
the duration and severity of hyperglycemia (DCCT 1996; 
UKPDS 2000). The role of hyperglycemia plays in induc-
ing these complications at a cellular level is now better 
understood. Within the retina itself, the classical ﬁ  nding is 
that of basement membrane thickening, which is associated 
with leakage and a loss of negative charge. Altered pericyte 
function, increased blood viscosity and altered ﬁ  brinolytic 
activity may lead to capillary occlusion with tissue hypoxia 
and, ultimately, new vessel formation. In addition to hyper-
glycemia, a number of other risk factors are associated 
with development or worsening of retinopathy, including 
hypertension, nephropathy, pregnancy, alcohol, smoking 
and ethnic origin (Shotliff et al 2005). The classiﬁ  cation of 
different forms of diabetic retinopathy is now well established 
(see Table 4).
Distinction between diabetic 
retinopathy and wet AMD
Diabetic retinopathy
Diabetic retinopathy is a characteristic group of lesions 
found in the retina of individuals who have had diabetes 
for a number of years. Successful management of glycemia 
reduces the risk of developing, and slows the progression 
of, retinopathy. However, in many cases, diabetic retinopa-
thy can result in progressive visual loss in well-controlled 
patients. It is important to realize that the natural history of 
diabetic retinopathy does not follow a standard timetable of 
progression; contrastingly, it has a rather variable course. 
Factors that most inﬂ  uence the evolution of the disease are 
the type and duration of diabetes, increased blood pressure 
and pregnancy. In the pre-clinical stage, alterations preced-
ing ophthalmoscopic changes have been demonstrated by a 
variety of more sensitive methods of examination and by his-
tological examination (Cunha-Vaz and Bernardes 2005).
Diabetic retinopathy is essentially a microangiopathy: 
its initial pathologic processes include endothelial prolif-
eration in the capillaries and venules, as well as endothelial 
swelling and apoptosis in the smallest arteriolar branchings. 
Table 3 The metabolic syndrome (modiﬁ  ed WHO deﬁ  nition) 
(Alberti et al 1998)
•   Fasting plasma glucose  6.1 mmol/L or hyperinsulinemia (upper quartile 
of the non-diabetic range), and
At least 2 of the following:
•   Abdominal obesity: BMI  30 kg/m2, waist-hip ratio  0.90 or waist circum-
ference  94 cm
•   Dyslipidemia: serum triglycerides  1.7 mmol/L or HDL cholesterol 
 0.4 mmol/L
•  Hypertension: blood pressure  140/90 mmHg or medication
Abbreviations: BMI, body mass index; HDL, high density lipoprotein.Clinical Ophthalmology 2008:2(2) 372
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Pericyte damage is also present, but its distribution is irregu-
lar and is only made more apparent because the affected cells 
are encased in basement membrane and thus take longer than 
endothelial cells to be replaced when damaged.
Fluorescein angiography conﬁ  rmed the histopathological 
ﬁ  ndings of diabetic retinal disease in a dynamic manner. It 
was the ﬁ  rst technique to document the abnormal leakage of 
ﬂ  uorescein through the walls of the retinal vessels, demonstrating 
a breakdown of the blood-retinal barrier (BRB).
Vitreous ﬂ  uorophotometry has been used to quantify the 
alteration of the BRB (Cunha-Vaz et al 1975). The method 
has conﬁ  rmed that alteration of the BRB.
When alterations of the fundus are detected by ophthal-
moscopy, it is said that non-proliferative diabetic retinopathy 
is present. The clinical features of non-proliferative diabetic 
retinopathy are: microaneurysms, intra-retinal hemorrhages, 
hard exudates and variable degrees of retinal edema. Retinal 
microaneurysms are usually the ﬁ  rst ophthalmoscopic sign 
of diabetic retinopathy. New microaneurysms are constantly 
being formed while older ones become occluded and the 
rate of formation of new microaneurysms may be the most 
relevant marker of disease progression. Retinal edema is a 
frequent ﬁ  nding that leads to distortion of visual images and 
may cause a signiﬁ  cantly decreased visual acuity, even in 
the relatively early stages of the retinopathy.
Stereoscopic fundus photography and slit-lamp micros-
copy have played an important role by demonstrating changes 
in retinal volume in the macular area, but findings are 
dependent on the observer’s experience, and the results do not 
offer a reproducible measurement of the volume change.
Two new techniques that make objective measurements of 
changes in retinal thickness have recently become available: 
optical coherence tomography (OCT) and the retinal thickness 
analyzer (RTA) (Zeimer et al 1989; Puliaﬁ  to et al 1995).
It is now possible to measure changes in retinal thick-
ness and identify macular edema using non-invasive 
instrumentation in a clinical setting. Diabetic macular edema 
may now be identiﬁ  ed by its type and distribution, evolution, 
pathophysiology, and by the degree of involvement of the 
central macular area (Cunha-Vaz 2006) (see Table 5).
Pre-proliferative diabetic retinopathy is an intermediate 
stage between non-proliferative and proliferative retinopathy. 
Widespread and increasing capillary closure is the 
fundamental feature of the pre-proliferative retinopathy 
stage. There are also soft exudates, venous beading and intra-
retinal microvascular abnormalities (IRMA). In addition, 
proliferative retinopathy is characterized by the presence of 
new vessels that may arise from the optic disk or from the 
retina periphery. These new vessels initially lie in the plane of 
the retina, but quickly pierce the internal limiting membrane 
and become pre-retinal, forming adhesions with the overlying 
vitreous. The presence of the new vessels leads to retraction 
of the vitreous. This pulling effect causes the progressive 
complications associated with retinal neovascularization, 
such as vitreous hemorrhage, progressive visual distortion 
and traction retinal detachment. Neovascularization always 
develops in eyes that show generalized and widespread 
capillary non-perfusion, again conﬁ  rming that it is a direct 
consequence of generalized ischemia.
Neovascular age-related macular 
degeneration
Age-related Macular Degeneration (AMD) occurs in two 
main forms: early (ie, dry) AMD and late (ie, neovascular/
exudative/wet) AMD (Ambati et al 2003).
Table 4 Classiﬁ  cation of diabetic retinopathy
Background retinopathy
Capillary microaneurysms (‘dots’)
Intraretinal hemorrhages (‘blots’)
Hard exudates (lipid exudates)
Pre-proliferative retinopathy
Soft exudates (cotton wool spots, infarcts)
Intra-retinal microvascular abnormalities (IRMAs)
Venous abnormalities (beading, looping, and re-duplication)
Proliferative retinopathy
New vessels on the disc or within one disc diameter (NVD)
New vessels elsewhere (NVE)
Rubeosis iridis (± neovascular glaucoma)
Maculopathy
Edematous
Exudative
Ischemic
Any combination of above
Table 5 Diabetic macular edema – characterization
Characteristics Focal  Diffuse
Chronicity Not  chronic  Chronic
Foveal involvement  Fovea preserved  Partial foveal involvement
BRB (inner)  No leakage  Open BRB
BRB (outer [RPE])  No RPE dysfunction  RPE dysfunction
OCT cysts  None  OCT cysts present
Traction None  Traction  present
Ischemia (FAZ)  None  Ischemia present
HbA1c HbA1c   8% HbA1c   8%
Blood pressure (BP)  BP   130/80 mmHg  BP  130/80 mmHg
Abbreviations: BRB, blood-retinal barrier; RPE, retinal pigment epithelium; FAZ, foveal 
vascular zone; HbA1c, glycated hemoglobin; OCT, optical coherence tomography.Clinical Ophthalmology 2008:2(2) 373
Treatment of neovascular age-related macular degeneration in patients with diabetes
The accepted clinical hallmark of dry AMD is the 
appearance of drusen: localized deposits lying between 
the basement membrane of the retinal pigment epithelium 
(RPE) and Bruch’s membrane. Clinically, drusen are clas-
siﬁ  ed morphologically as either hard or soft. Soft drusen 
are generally larger and have indistinct edges, and have 
a tendency to become conﬂ  uent. Typically, drusen are 
clustered in the central macula, where the pathological 
abnormalities in AMD are most pronounced. At various 
stages, the RPE, photoreceptors and choroidal vasculature 
are involved.
Geographic atrophy is characterized by the presence of 
conﬂ  uent areas of RPE cell damage accompanied by overlying 
photoreceptor atrophy. Geographic atrophy can develop 
following fading of drusen, in areas of RPE attenuation, 
following flattening of an RPE detachment, or after 
involution of choroidal neovascularization (CNV). The visible 
atrophy is usually accompanied by an atrophic underlying 
choriocapillaris. Both geographic atrophy and CNV tend to 
develop in patients with large drusen and pigmentary changes. 
Patients with bilateral atrophy can develop CNV at a rate of 
2%–4% over a 2-year period.
The development of CNV (ie the growth of new blood 
vessels from the choroids) is the hallmark of neovascular 
(or exudative/wet) AMD. In AMD, the new vessels can 
remain beneath the RPE, or may breach the RPE and enter 
the retina space. The earliest signs of CNV are retinal edema 
and visual distortions.
The ﬂ  uorescein angiographic leakage patterns of CNV 
are classiﬁ  ed as either classic or occult. The former refers to 
discrete areas that hyperﬂ  uoresce early in the examination 
and continue to exhibit progressive leakage with increasing 
intensity and extent. Occult CNV refers either to a 
ﬁ  brovascular RPE detachment with irregular elevation of 
the RPE, with stippled hyperﬂ  uorescence and late leakage, 
or to late leakage of undetermined origin.
Retinal edema is particularly well demonstrated by OCT 
examination, and is indicated by an increase in thickness of 
the retina. It is one of the most widely accepted criteria for 
treatment and re-treatment of neovascular AMD. There are two 
special subtypes of wet AMD that are better identiﬁ  ed with 
indocyanine green angiography (ICG): chorioretinal anasto-
moses and polypoidal-choroidal neovascularization (Slakter 
et al 2000; Yannuzzi et al 1990). The two exhibit different 
patterns of disease progression and have different prognoses. 
The Disciform Scar Represents End-Stage Disease.
Diabetic retinopathy and neovascular AMD are the 
two most frequent retinal degenerative diseases and are 
responsible for the majority of cases of blindness due to 
retinal disease. The two conditions predominantly affect 
the central macula; their development is associated with the 
presence of retinal edema and an aggressive inﬂ  ammatory 
repair process that accelerates disease progression. Both 
the retinal edema and the inﬂ  ammatory repair process are 
directly associated with breakdown of the BRB. However, 
the underlying alterations to the BRB are very different 
in these two diseases. Diabetic retinopathy is, initially, a 
disease of the inner layers of the retina, beginning with an 
alteration of the inner BRB, located in the retinal endothelial 
cells. Contrastingly, neovascular AMD initially affects the 
outer retinal layers and starts at the chorioretinal interface 
(with an alteration of the outer BRB), located in the retinal 
pigment epithelium, which then allows invasion of the retina 
by neovessels located in the choriocapillaries.
Treatment of neovascular AMD 
in patients with diabetes
The population-based Framingham Eye Study, in addition 
to a number of other case-controlled studies, failed to ﬁ  nd 
an association between macular degeneration and diabetes 
mellitus. Data from the Beaver Dam Study (Klein et al 1992) 
suggest that diabetes is not related to macular drusen or 
geographic atrophy. The only association demonstrated was 
that between exudative macular degeneration and diabetes 
in men aged 75 years or older.
In a different study (Zylbermann et al 1997), the preva-
lence of neovascular AMD in patients with diabetic reti-
nopathy was only 0.86%, which is lower than the prevalence 
in the general population. Furthermore, the investigators 
reported that patients treated with laser photocoagulation 
for diabetic retinopathy are less prone to the development 
of neovascular AMD.
More recently, data were reported from a 10-year follow-
up study of newly diagnosed patients with type 2 diabetes in 
Finland (Voutilainen-Kaunisto et al 2000). The study dem-
onstrated that the incidence of neovascular AMD over time 
was possibly lower in the patients with diabetes compared 
with control subjects.
Furthermore, the diabetic retinopathy fundus photography 
screening program in progress in the central region of Portu-
gal has detected an incidence of diabetic retinopathy in 2.6% 
of patients with type 2 diabetes, but an incidence of only 
0.4% of all types of AMD (and 0.05% of neovascular AMD). 
These values are clearly lower than the values reported for 
the general population, even taking into consideration the 
age of the patients examined.Clinical Ophthalmology 2008:2(2) 374
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Therefore, it may be concluded from both literature and 
clinical experience that diabetes may offer some degree of 
protection from the development of neovascular AMD.
Current opinion in neovascular 
AMD treatment
Although laser photocoagulation was the only treatment avail-
able for many years, it is now only accepted for treatment of 
patients with well deﬁ  ned, extrafoveally located CNV. Photo-
dynamic therapy (PDT), which was approved in 2000 predomi-
nantly for the treatment of CNV, has been shown to prevent 
progression of vision loss when compared with controls, but the 
main result is temporary stabilization of visual acuity loss.
Combining PDT with anti-inﬂ  ammatory drugs (such as 
triamcinolone or other steroids) has offered improved visual 
outcomes through a reduction of the inﬂ  ammation caused 
by PDT. However, the use of steroids can induce several 
complications. In an attempt to deal with these problems, a 
variety of sustained-release devices have been introduced to 
modulate drug delivery to the eye.
Although the current evidence base is inconclusive, it 
is expected that the inﬂ  ammatory repair responses present 
in both diabetic retinopathy and neovascular AMD may be 
cumulative and may be compounded when wet AMD is pres-
ent in eyes of patients with diabetic retinal disease.
Vascular endothelial growth factor (VEGF) inhibitors are 
now being used for the treatment of eyes with neovascular 
AMD, and have shown a signiﬁ  cant degree of success. Treat-
ment with these anti-VEGF agents has even demonstrated 
that a degree of recovery of visual function, followed by 
stabilization of such recovery, is possible. Pegaptanib sodium 
(Macugen®, [OSI] Eyetech Pharmaceuticals Inc, New York 
NY, USA), a selective inhibitor of VEGF, has shown efﬁ  -
cacy in trials including all angiographic types of neovascular 
AMD (Gragoudas et al 2004). The series of trials, together 
termed VISION, were speciﬁ  cally designed not to differenti-
ate patients on angiographic indications, but rather with the 
intention of validating the hypothesis that selective inhibition 
of VEGF could provide a safe and effective treatment for 
patients of all subtypes of neovascular AMD.
Ranibizumab (Lucentis®, Genentech Inc, South San 
Francisco, CA, USA) is a non-selective anti-VEGF agent and 
approaches inhibition of VEGF in more general terms. In clin-
ical trials (Brown et al 2006; Rosenfeld et al 2006), the agent 
has demonstrated that it not only stabilizes the progression 
of neovascular AMD, but can also lead to an improvement 
in vision in patients with speciﬁ  c subtypes of the disease. A 
series of anecdotal reports have conﬁ  rmed these ﬁ  ndings with 
bevacizumab (Avastin®, Genentech Inc, South San Francisco, 
CA, USA), a drug of the same class, but which is indicated 
for colorectal cancer and has no license for use in the eye, and 
has not been submitted for clinical trial evaluation.
Addressing CNV with a non-selective VEGF inhibition, 
as is the approach of ranibizumab, has demonstrated better 
visual outcomes. These data may suggest that selective inhi-
bition of VEGF is an important component of combating the 
disease process, but that there are also other factors present 
that require treatment. This argument favors combination 
approaches for treatment of neovascular AMD.
Treatment of neovascular AMD 
in patients with diabetes
There are at least two important factors to consider when 
treating neovascular AMD in patients with diabetes: the 
role of retinal edema in the modulation of treatment and the 
relevance of associated side effects of the treatment.
Evaluation of treatment and re-treatment timing is now 
very much associated with the degree and evolution of retinal 
edema detected by OCT. Retinal edema is the most frequent 
alteration in the diabetic retina and its presence may delay 
recovery and drying of the retina immediately after treatment 
for neovascular AMD.
Also of note is the consideration of potential side effects 
that may be induced by repeated treatments with less selective 
anti-VEGF agents. Any such side effects may be particularly 
relevant in patients with diabetes, in light of their associated 
micro- and macrovascular complications.
Conclusions
Current evidence demonstrates that the coexistence of diabetic 
retinopathy and neovascular AMD is uncommon, potentially 
suggesting that diabetes may offer a protective role against the 
development of neovascular AMD. This interesting hypoth-
esis may be explained by the fact that each disease is initiated 
by selective involvement of one of the two components of 
the BRB. The early stages of diabetic retinopathy begin with 
alterations of the inner BRB, whereas AMD involves the 
outer BRB. There is some evidence in the literature indicating 
that, in the case of diabetic retinal edema, there is signaling 
from the damaged inner BRB that induces up-regulation of 
the transport function of the RPE (outer BRB) (Sander et al 
2001). As a result, diabetic retinal disease may help delay 
development of the AMD alterations that lead to wet AMD.
In patients with diabetes who require treatment for neo-
vascular AMD, the choice of therapy and timing of treatments 
and re-treatments (based on degree of retinal edema measured Clinical Ophthalmology 2008:2(2) 375
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by OCT), should take into consideration the association of 
diabetic retinopathy and the possible presence of chronic dif-
fuse cystoid edema. Another factor that must be considered in 
patients with diabetes is their potential increased susceptibil-
ity to the side effects associated with the drugs administered 
repeatedly for neovascular AMD treatment.
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